Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics

Categories

[Search within category]

Small Molecule Regulators of let-7 MicroRNA Targets in Acute Myeloid Leukemia Cancer Stem Cells

UCLA researchers have identified a class of small molecule phosphodiesterase inhibitors that suppress let-7 target genes and inhibit cell growth in acute myeloid leukemia cancer cell lines.

Mucoadhesive Devices for Oral Delivery of Various Active Agents

Effective and easily accepted system of oral delivery of therapeutic drugs.

Method for creating a macular/retinal degeneration animal model

Researchers at UCI have developed an animal model that mimics the onset and progression of age-related macular degeneration, an incurable disease that is the fourth-leading cause of blindness globally. The model serves as a means for testing the efficacy of possible treatments and cures.

A New Therapeutic Approach To Create And Exploit Metabolic Vulnerabilities In Malignant Glioma And Other Cancers

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a novel cancer therapeutic approach that targets both metabolism and cell death signaling pathways, creating a synergistic killing effect that vastly increases treatment efficacy.

Pathway-Dependent Inhibition Of Proteopathic Seed Transmission

UCLA researchers in the Department of Neurology have developed a novel approach to stop the propagation of proteopathic diseases, which could be applied to wide range of neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease.

Bioorthogonally-Engineered Extracellular Vesicles for Applications in Detection and Therapeutic Delivery

Extracellular vesicles (EVs) are promising as drug delivery carriers because they are inherently biocompatible, It would be desirable to efficiently, specifically, and rapidly change the EVs surface presentation to program the interactions with its target cells. Inventors at UC Irvine have developed a strategy for functionalizing the cellular membranes of EVs with precision and ease.

Antimicrobial, Stimuli-responsive Polysaccharide

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

Biomarkers for Port Wine Stain and Related Syndromes

Researchers at the University of California, Irvine (UC Irvine) have discovered specific biomarkers that will enable innovations in diagnosis, prognosis, monitoring, and therapy of PWS and other related syndromes.

A High Dynamic-Range Sensing Front-End For Neural Signal Recording Systems

UCLA researchers in the Department of Electrical Engineering have invented a novel neural recording chopper amplifier for neuromodulation systems that can simultaneously record and stimulate.

Immunotherapy Against Aß-Mediated Inhibition of ADAM10 Activity

UCLA researchers in the Department of Neurology have developed a novel immunotherapy targeting a previously unexplored pathway of Aβ toxicity in Alzheimer’s disease.

Immunotherapy for Treatment of Neuromyelitis Optica (NMO)

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

Controlled-Release Cysteamine Nanowafer For Treating Corneal Cystinosis

Corneal cystinosis is a rare metabolic disease that causes loss of vision. Researchers at UCI have developed a nanowafer drug delivery system that has demonstrated twice the therapeutic efficacy during in vivo studies in mice.

Predictive Optimization Of Pharmeceutical Efficacy

UCLA researchers in the Department of Mechanical and Aerospace Engineering have developed a machine learning platform to virtually screen combinatorial drug therapies.

Macrophage Programming for Immunotherapy

Immunotherapy is one of the most important areas in modern medicine. Using antibodies, proteins, and cells, physicians are now able to target a range of conditions with specificity. UC San Diego researchers have recently developed a new process for engineering macrophages to possess a broad range of sensing and programed actions for directed therapeutics.

Identification of Novel NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome is a molecular machine that becomes activated during acute and chronic inflammation and leads to production of biologically active IL-1β and IL-18 that initiate inflammatory responses triggered by tissue damage. The NLRP3 inflammasome has also been implicated in many chronic inflammatory and degenerative diseases from gout, osteoarthritis, atherosclerosis to Alzheimer’s disease. Currently, there are no effective ways to inhibit the NLRP3 inflammasome, thus there is a therapeutic need for this class of molecule.

Directed Editing Of Cellular RNA Via Nuclear Delivery Of CRISPR/Cas9

CRISPR-Cas9 technology has revolutionized the field of biological research through the introduction of sequence-specific genomic manipulation at the DNA level. It has also been reported that catalytically-dead Cas9 (dCas9) can successfully be localized to specific mRNAs within live cells. However, no system exists to perform Cas9-mediated sequence editing at the RNA level.

Diels-Alder Chemistry for Bioconjugation and Incorporation into Non-Natural Amino Acids

A bioconjugation method to covalently link molecular entities to polypeptides such as antibodies using a simple one-pot process.

TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

Novel Methodology To Convert Magnetic Resonance Imaging Scan Data To Be Used In Proton Beam Therapy

This invention is a novel model that uses magnetic resonance imaging (MRI) information to more accurately determine the irradiation area using proton beam therapy (PBT) for oncological treatment.

Generation of an Improved Synthetic Splice Modulator (FDGLY) That Mirrors the Structural Features of the Potential CLL In Vitro Inhibitor FD-895

 An increasing body of research has shown that alternations in RNA splicing are involved in a number of human diseases, particularly cancer. Drug regulation of splicing has become an interesting new target for therapeutic discovery. A number of drug discovery efforts aimed at developing splicing-modulating small-molecules are being tested in clinic trials for cancer.

Active Nanoplatform with High Drug Loading Capacity for the Diagnosis and Treatment of Cancer

Researchers at the University of California, Davis have developed an active nanoplatform (F/HAPIN) for cancer diagnosis and therapy.

Structurally Validated Anti-avß8 Antibodies for Targeting TGFß for Immunotherapy

This invention provides highly efficient antibodies whose epitopes and mechanism of action have been structurally defined against integrin αvβ8. These antibodies have been designed to be used as therapeutic for cancer. Other antibodies have been designed as companion diagnostic tools.

Nell-1 Regulates Neurogenesis And Nervous System Function

UCLA researchers in the Division of Plastic and Reconstructive Surgery at the Geffen School of Medicine and researchers at the School of Dentistry have identified neural EGFL Like 1 (Nell-1) protein as an essential molecule involved in neurogenic development and nervous system functional regulation.

Novel Covalent Inhibitors Of GTP And GDP-bound RAS

This invention describes a novel class of direct Ras inhibitors that bind and inhibit this oncogene in its GTP and GDP-bound states.

  • Go to Page: